Literature DB >> 26369829

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.

A G Dinmohamed1, Y van Norden2, O Visser3, E F M Posthuma4, P C Huijgens3,5, P Sonneveld1, A A van de Loosdrecht5, M Jongen-Lavrencic1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26369829     DOI： 10.1038/leu.2015.220

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

Authors:  Lewis R Silverman; Pierre Fenaux; Ghulam J Mufti; Valeria Santini; Eva Hellström-Lindberg; Norbert Gattermann; Guillermo Sanz; Alan F List; Steven D Gore; John F Seymour
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

2.  Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Authors:  T Bernal; P Martínez-Camblor; J Sánchez-García; R de Paz; E Luño; B Nomdedeu; M T Ardanaz; C Pedro; M L Amigo; B Xicoy; C del Cañizo; M Tormo; J Bargay; D Valcárcel; S Brunet; L Benlloch; G Sanz
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

3.  Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.

Authors:  Avinash G Dinmohamed; Otto Visser; Yvette van Norden; Peter C Huijgens; Pieter Sonneveld; Arjan A van de Loosdrecht; Mojca Jongen-Lavrencic
Journal:  Eur J Cancer       Date:  2013-12-31       Impact factor: 9.162

4.  The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.

Authors:  Avinash G Dinmohamed; Yvette van Norden; Otto Visser; Eduardus F M Posthuma; Peter C Huijgens; Pieter Sonneveld; Arjan A van de Loosdrecht; Mojca Jongen-Lavrencic
Journal:  Leuk Res       Date:  2014-12-04       Impact factor: 3.156

5.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.

Authors:  Steven D Gore; Pierre Fenaux; Valeria Santini; John M Bennett; Lewis R Silverman; John F Seymour; Eva Hellström-Lindberg; Arlene S Swern; Charles L Beach; Alan F List
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

8.  Completeness of cancer registration in Limburg, The Netherlands.

Authors:  L J Schouten; P Höppener; P A van den Brandt; J A Knottnerus; J J Jager
Journal:  Int J Epidemiol       Date:  1993-06       Impact factor: 7.196
  8 in total
  10 in total

1.  Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.

Authors:  T Bernal; P Martínez-Camblor; J Sánchez-García; G Sanz
Journal:  Leukemia       Date:  2016-01-12       Impact factor: 11.528

2.  Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†.

Authors:  Amy J Davidoff; Xin Hu; Jan Philipp Bewersdorf; Rong Wang; Nikolai A Podoltsev; Scott F Huntington; Steven D Gore; Xiaomei Ma; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2019-12-26

3.  Effectiveness of azacitidine in higher-risk myelodysplastic syndromes.

Authors:  A G Dinmohamed; Y van Norden; A A van de Loosdrecht; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2016-05-20       Impact factor: 11.528

4.  In MDS, is higher risk higher reward?

Authors:  Guillermo F Sanz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

5.  Integrating patient-centered factors in the risk assessment of MDS.

Authors:  Rena J Buckstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.

Authors:  Johanne Rozema; Mels Hoogendoorn; Robby Kibbelaar; Eva van den Berg; Nic Veeger; Eric van Roon
Journal:  Blood Adv       Date:  2021-03-09

7.  Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.

Authors:  Michael Leisch; Michael Pfeilstöcker; Reinhard Stauder; Sonja Heibl; Heinz Sill; Michael Girschikofsky; Margarete Stampfl-Mattersberger; Christoph Tinchon; Bernd Hartmann; Andreas Petzer; Martin Schreder; David Kiesl; Sonia Vallet; Alexander Egle; Thomas Melchardt; Gudrun Piringer; Armin Zebisch; Sigrid Machherndl-Spandl; Dominik Wolf; Felix Keil; Manuel Drost; Richard Greil; Lisa Pleyer
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 8.  Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

9.  Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Authors:  Lisa Pleyer; Hartmut Döhner; Hervé Dombret; John F Seymour; Andre C Schuh; C L Beach; Arlene S Swern; Sonja Burgstaller; Reinhard Stauder; Michael Girschikofsky; Heinz Sill; Konstantin Schlick; Josef Thaler; Britta Halter; Sigrid Machherndl Spandl; Armin Zebisch; Angelika Pichler; Michael Pfeilstöcker; Eva M Autzinger; Alois Lang; Klaus Geissler; Daniela Voskova; Wolfgang R Sperr; Sabine Hojas; Inga M Rogulj; Johannes Andel; Richard Greil
Journal:  Int J Mol Sci       Date:  2017-02-15       Impact factor: 5.923

10.  Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

Authors:  Magnus Tobiasson; Donal P McLornan; Mohsen Karimi; Marios Dimitriou; Monika Jansson; Asmaa Ben Azenkoud; Martin Jädersten; Greger Lindberg; Hani Abdulkadir; Austin Kulasekararaj; Johanna Ungerstedt; Andreas Lennartsson; Karl Ekwall; Ghulam J Mufti; Eva Hellström-Lindberg
Journal:  Oncotarget       Date:  2016-04-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.